INTRODUCTION {#s1}
============

Despite the success of antiretroviral therapy (ART) in preventing HIV disease progression, ART does not eradicate the virus. Integrated viral DNA persists in reservoirs of latently infected resting CD4^+^ T cells and in lymphoid tissues, which develop soon after HIV acquisition during acute HIV infection (AHI).^[@R1]--[@R4]^ Serial sampling of these tissues can provide important information about HIV reservoirs and immune responses, advancing our understanding of HIV pathogenesis and informing HIV cure efforts.

Lymph node (LN) biopsies are safe in both chronically HIV-infected and HIV-uninfected populations.^[@R5]--[@R7]^ Complications of LN biopsy have included surgical site infection, seroma, hematoma, lymphedema, lymphocele, dorsal vein thrombosis, and epididymitis.^[@R5]--[@R7]^ However, only one study has examined the safety of LN biopsy in an HIV-infected population outside the United States.^[@R7]^ No studies have been conducted on AHI.

Unlike the steady-state viremia and immune dysfunction in untreated chronic HIV infection, AHI is associated with a surge of viral replication and immune activation, particularly in lymphoid tissues.^[@R8],[@R9]^ It is unknown whether complications from tissue biopsies may be more common during this period. It is critical for researchers to understand the safety of invasive procedures performed in a variety of settings and at various stages of infection to optimally use these procedures during clinical research programs and to adequately inform research participants about the risks of study participation. Here, we examine the safety of inguinal LN biopsies in a prospective cohort of participants with AHI in Bangkok, Thailand.

METHODS {#s2}
=======

Study Population {#s2-1}
----------------

The RV254/SEARCH010 study prospectively screened and enrolled participants with AHI from the Thai Red Cross Anonymous Clinic in Bangkok, Thailand ([clinicaltrials.gov](http://clinicaltrials.gov) identification number NCT00796146). The study was approved by the institutional review boards of the Chulalongkorn University in Thailand and the Walter Reed Army Institute of Research in the United States. Informed consent was obtained separately for the main study and for optional procedures, which included inguinal LN biopsy. Participants in RV254/SEARCH010 who underwent LN biopsy are included in these analyses.

Participant Identification and Staging {#s2-2}
--------------------------------------

The RV254/SEARCH010 study used pooled nucleic acid testing, fourth generation (4thG) HIV antigen/antibody immunoassay, and sequential less sensitive HIV antibody immunoassay to identify and enroll acutely HIV-infected participants attending a major voluntary counseling and testing site in Thailand, as previously described.^[@R10],[@R11]^ Staging of AHI was performed using Fiebig staging.^[@R12]^ The number of days since HIV exposure was estimated using an algorithm that considers sexual encounters of varying risk levels over the preceding 30--60 days, as previously described.^[@R13]^ Participants in RV254/SEARCH010 were offered ART during AHI through a separate protocol ([clinicaltrials.gov](http://clinicaltrials.gov) NCT00796263). They were followed at days 0, 3, 7; weeks 2, 4, 8, 12; and then every 12 weeks.

Inguinal LN Biopsy Procedure {#s2-3}
----------------------------

Inguinal biopsies were offered at enrollment and after 24, 48, 96, 144, and 240 weeks in the study, with a maximum of 4 LN biopsies per participant allowed. LNs were identified by palpation. The biopsies were performed in the inguinal region by 2 experienced surgeons using local anesthesia and standard sterile technique. A single LN was removed through a 1--2-cm skin incision that was closed with sutures.

Repeated biopsies were performed on the side of the groin opposite to the previous biopsy. Participants were instructed to avoid strenuous activities for 24 hours after each procedure and advised to contact the study team in the event of any sign or symptom of postoperative complications. At the next scheduled study visit after the procedure, study physicians asked participants for feedback and adverse events (AEs) related to the biopsy. Participants were given the option to undergo photography of the biopsy wound immediately after the procedure.

Participants were excluded from the procedure if they had clinical bleeding abnormalities; platelet count below 80,000/mL or INR \> 1.2; or had taken aspirin, nonsteroidal anti-inflammatory drugs, or anticoagulant medications within the previous 7 days.

AE Monitoring and Grading {#s2-4}
-------------------------

Participants were asked to contact the study team after the procedure if any abnormal symptoms developed, and AEs were solicited and graded at every study visit by study physicians. Physicians recorded the start and end dates of the AE and association to ART or procedures. Complications of LN biopsies were evaluated retrospectively using the study database and medical record review.

AEs were graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0.^[@R14]^ The DAIDS table was selected because it is a standardized and sequential scale for classifying complications. Grade 1 is characterized as "mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated," grade 2 as "moderate symptoms causing greater-than-minimal interference with usual social and functional activities with intervention indicated," grade 3 as severe, and grade 4 as AEs that are potentially life-threatening.^[@R14]^

Statistical Methods {#s2-5}
-------------------

Data were summarized by median with interquartile range (IQR) for continuous variables and number with percentage for categorical variables. Incidence rate ratios (IRRs) of AE and 95% confidence interval (CI) were calculated using Poisson distribution. Longitudinal Poisson regression models were used to assess whether age, plasma HIV RNA, CD4 cell count, and sexually transmitted infections (including chlamydia, gonorrhea, and syphilis) at the time of biopsy were associated with AE incidence. Separate analyses evaluated whether baseline procedures were associated with the number of AEs and whether repeating a biopsy procedure more than once increased AE risk. Factors with a *P*-value \<0.05 were considered significant. All analyses were performed using Stata Statistical Software Release 13 (StataCorp, College Station, TX).

RESULTS {#s3}
=======

Study Population Characteristics {#s3-1}
--------------------------------

Between June 2013 and May 2016, 67 acutely HIV-infected participants in the RV254/SEARCH 010 study (97% male, median age 26 years) consented to and underwent LN biopsy as an optional procedure. All biopsies that were attempted during this period were successful in removing LNs. Isolated LNs were a median of 13 mm (IQR 9--17 mm) at AHI and 12 mm (IQR 9--15 mm) at follow-up. Fifty-six participants underwent one LN biopsy and 11 participants underwent 2 procedures, although up to 4 biopsies were allowed per study protocol. A total of 78 LN biopsies were completed during the study period, 39 procedures during AHI at baseline and 39 at a follow-up visit, 24--240 weeks after ART initiation. Clinical characteristics of participants are summarized in Table [1](#T1){ref-type="table"}.

###### 

Characteristics of Participants With Completed Lymph Node Biopsy

![](qai-79-244-g001)

Safety of Optional Inguinal LN Biopsy {#s3-2}
-------------------------------------

Among the 78 inguinal LN biopsies performed, there were a total of 10 procedure-related AEs (Table [2](#T2){ref-type="table"}) for an overall AE rate of 12.8%, including 6 that were mild (grade 1, 7.7%) in severity and 4 that were moderate (grade 2, 5.1%). No participant encountered more than one AE associated with LN biopsy. The grade 1 AEs all resolved without any medical intervention. Prolonged biopsy-site discomfort was the most common grade 1 AE and persisted for a range of 10 days to 1 month.

###### 

Complications Associated With Biopsy and Association Factors

![](qai-79-244-g002)

Two out of 3 of the grade 2 biopsy site discomfort AEs presented swelling, which resolved without treatment. In one participant with grade 2 biopsy-site discomfort, the wound was painful when sitting, and swelling was approximately 8 × 4 cm at 2 weeks after procedure when the study physician and surgeon inspected the biopsy site. No treatment was necessary and the wound healed without complications after 1.5 months. The second case presented discomfort when walking and swelling, which resolved 20 days after the procedure. The final case of grade 2 biopsy site discomfort was managed by 1000 mg of paracetamol daily and resolved within 9 days. A single complication of grade 2 hematoma healed within 10 days of the procedure. The participant was also treated with 1000 mg of paracetamol daily and received amoxicillin as a prophylactic antibiotic after the biopsy.

Factors Associated With LN Biopsy--Related AEs {#s3-3}
----------------------------------------------

Eight of the reported AEs were associated with biopsies during AHI, and the remaining 2 occurred after procedures performed at later study visits (Table [2](#T2){ref-type="table"}). Although numerically more AEs occurred during AHI than during later study visits, the difference in event rates did not achieve statistical significance \[IRR 4.00 (95% CI: 0.85--18.84), *P* = 0.08\]. The rate of AEs was also higher in participants with detectable plasma HIV RNA, although not statistically significant \[IRR 3.80 (95% CI: 0.81--17.89), *P* = 0.09\]. Age, CD4 cell count, and sexually transmitted infections were not associated with AE incidence. No participant who completed an LN biopsy during AHI had viral load below 50 copies per milliliter, whereas 38 of 39 participants who completed biopsy at a later follow-up visit were fully suppressed (Table [1](#T1){ref-type="table"}). Undergoing 2 LN procedures did not significantly increase AE risk.

DISCUSSION {#s4}
==========

Inguinal LN biopsies for research purposes were safe and well tolerated in this cohort of mostly young Thai men with AHI. Although AEs were reported in 12.8% of procedures, most required little or no intervention and did not substantially interfere with daily functions. All AEs resolved without sequelae.

For LN biopsy--associated complications, the grade 1 AE rate in the RV254/SEARCH010 study was 7.7%, which was slightly lower than the rate for minor complications reported by an HIV-infected cohort study in the United States.^[@R6]^ The grade 1 AEs in our study, which did not require medical intervention, were similar to the "minor complications" in the U.S. study. While that study reported 6 seromas, 1 lymphedema, 1 hematoma, and 1 reaction to adhesive tape in 95 procedures, our grade 1 AEs seemed milder in comparison: 5 cases of biopsy-site discomfort and 1 hematoma.^[@R6]^ Biopsy-site discomfort was not reported in previous studies most likely because it was considered expected and relatively minor from the surgical perspective.

The majority of complications reported in previous reports seem to commensurate with grade 2 AEs by the DAIDS grading table.^[@R14]^ Our grade 2 LN-associated AE rate was 5.1%, comparable with the complication rate of 5%--10% reported in other HIV cohorts.^[@R5],[@R6]^ Rothenberger et al^[@R7]^ reported a 2.4% (1/41 procedures) complication rate in HIV-infected participants but used a different methodology for defining AEs. Our complication rate is also similar to the reported rates of LN-related AEs in HIV-uninfected populations in Netherlands and Germany.^[@R15],[@R16]^

Although not statistically significant, more AEs were reported at baseline during AHI than at follow-up and in study participants with detectable plasma HIV RNA, defined as ≥20 copies per milliliter. All participants with AEs during AHI had viral loads above 50 copies per milliliter, whereas all participants with AEs at follow-up were below (HIV RNA \< 50 copies/mL). Viremia and immune activation during AHI could theoretically increase susceptibility to biopsy-related complications.^[@R8]^ The more frequent follow-up shortly after baseline (6 visits within the first 4 weeks) as compared with later follow-up visits (every 12 weeks) may have contributed to more AEs being documented for biopsies during AHI.

The DAIDS AE grading table used in our study offered a standardized method of rating complications and is specific to HIV research, which likely increased sensitivity in detecting AEs as compared with previous studies of LN biopsy--related AEs. Unlike surgical grading table, this system does not include common surgical complications such as seromas and wound infections.^[@R17]^ Comparability between studies is therefore limited---our analysis in participants with AHI included mild, grade 1 AEs that did not compromise the safety of the procedure and most likely were not reported by other studies. We did not encounter rare or serious AEs. Findings from young Thai males may not be generalizable to other populations.

CONCLUSIONS {#s5}
===========

Inguinal LN biopsies are safe and well tolerated by participants with AHI in Thailand. Biopsy-related AEs occurred in 12.8% of participants and were mild and self-limited. Biopsy-site discomfort was the most common AE. As LN biopsies become an integral part of HIV research, this study provides information to participants, researchers, and institutional review boards that these samples can be safely obtained.
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